Pfizer Deepens Investment in CytoReason for Novel Drug Discovery and Development

Company of the Year 2022: Pfizer – Building on Covid-19

Follow the Money: NIH Funds Brain Mapping Network Initiative, Non-Invasive Skin Patch for Vaccine Delivery, More

CytoReason and Pfizer extend their alliance for AI delivery in drug discovery

Pfizer strengthens AI drug discovery collaboration with equity investment

Pfizer Extends Collaboration With Disease Model Co CytoReason

Israeli AI company CytoReason expands contract with US company Pfizer, raises up to approximately 15.4 billion yen

Pfizer extends its faith in CytoReason for AI-driven drug discovery

Pfizer and CytoReason collaborate to bolster AI in drug discovery

Pfizer and CytoReason extend partnership for AI-driven drug discovery
